Forest Laboratories
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Forest Laboratories sits in the top decile of US sponsors by registered trial count (#194 of 15,742 sponsors by registered trial count).
Forest Laboratories: 145 sponsored US clinical trials, none currently recruiting.
Forest Laboratories sponsors 145 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 127 completed. 100 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 9 trials.
Top-decile sponsor footprint
Forest Laboratories ranks in the top decile of sponsors by registered trial count (#194 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 145 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
145 total, page 1 of 3
Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage
NCT02788617
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
NCT02732327
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
NCT02670538
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
NCT02670551
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
NCT02559570
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
NCT02590432
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
NCT02559817
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
NCT02431806
A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
NCT02436239
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
NCT02372799
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
NCT02288325
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
NCT02270983
A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
NCT02220348
Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo
NCT02097147
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
NCT01878292
Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder
NCT01844115
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
NCT01838876
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
NCT01766401
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
NCT01701219
Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
NCT01617200
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
NCT01715805
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
NCT01669980
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
NCT01645735
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
NCT01592773
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
NCT01592747
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
NCT01530763
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
NCT01642914
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
NCT01629966
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
NCT01592786
Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance
NCT01624246
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
NCT01395992
Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01573598
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
NCT01508026
A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021
NCT01498497
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
NCT01469377
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections
NCT01400867
Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder
NCT01473394
Safety and Efficacy of Vilazodone in Major Depressive Disorder
NCT01473381
Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)
NCT01396291
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
NCT01464476
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
NCT01412060
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
NCT01386112
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
NCT01415531
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
NCT01415505
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
NCT01313572
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
NCT01396447
Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
NCT01376076
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
NCT01377194
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
NCT01328002
Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
NCT01298843
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 34 |
| Phase 3 | 75 |
| Phase 4 | 25 |
How the Forest Laboratories archive is shaped
145 indexed studies, none listed as recruiting (0% open); 127 completed (88%).
Phase mix: 100 late (III/IV) vs 43 early (I/II) (later-stage heavy).
Top condition: Major Depressive Disorder (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Forest Laboratories: archived-pipeline peers nationwide
Peers matched on 145 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Forest Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 145 archived trials
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
- HealthPartners Institute · 146 trials · 8% recruiting
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- SCRI Development Innovations · 146 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Forest Laboratories page
145 registered trials is a research-attention snapshot, not an endorsement of Forest Laboratories or any single study.
- None of Forest Laboratories's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Major Depressive Disorder is the condition Forest Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Forest Laboratories pipeline card: 145 registered trials from official public datasets.Report a data error.